Last week I wrote about the many potentials of
Cytori Therapeutic's Celution system that extracts stem and other regenerative cells from a patient's own fat cells. Today, the potential for the expansion of the platform to treat gum disease was highlighted in
pre-clinical study results released in a
press release from Cytori. The results suggest that the use of uncultured fat derived regenerative cells significantly improved the effects of periodontal disease, evidenced by significantly improved alveolar bone healing and decreased gingival (gum) invasion of the defect.
Of course, this data is
pre-clinical in nature and must pass clinicical trials in humans. However, it illustrates my underlying investment thesis on the vast potential of
Cytori's PLATFORM:
ONE MEDICAL TECHNOLOGY-----> MULTIPLE POTENTIAL APPLICATIONS
I expect more positive data over the next six months and believe the stock will react positively.
These are the personal views of The
Sirtuin Investor. Do your own due diligence.
No comments:
Post a Comment